Hanna P. Lesch

Ferring Pharmaceuticals (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.7kcitations52works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(33), Viral Infectious Diseases and Gene Expression in Insects(21), CAR-T cell therapy research(11), RNA Interference and Gene Delivery(9), Viral gastroenteritis research and epidemiology(6)

Publications52 total

Novel, Stable, and Well-Secreted Single-Chain Fc Forms of Programmed Death-1 Immune Checkpoint Inhibitor Efficiently Block PD-1/PD-L1 Interaction
Human Gene Therapy·2026
The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice
Gene Therapy·2026Open Access
CGT 4.0: a distant dream or inevitable future? Smart process automation is critical to make efficient scalability of CGT manufacturing a reality
Frontiers in Bioengineering and Biotechnology·2025· 2 citedOpen Access
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing
Cytotherapy·2024· 2 citedOpen Access
Supplementary Figure 1 from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Data from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure Legend from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Data from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure Legend from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Supplementary Figure 1 from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
2023Open Access
Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
Frontiers in Medicine·2023Open Access
Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
Frontiers in Medicine·2022· 14 citedOpen Access
Functional roles of the membrane-associated AAV protein MAAP
Scientific Reports·2021· 50 citedOpen Access
Experimental Evaluation of an Interferometric Light Microscopy Particle Counter for Titering and Characterization of Virus Preparations
Viruses·2021· 22 citedOpen Access
Pricing Pressure of Advanced Therapy Medicinal Products can be Diminished by Contemporary Manufacturing Process Development
Gene Technology·2021Open Access
Evaluation of the Single‐Use Fixed‐Bed Bioreactors in Scalable Virus Production
Biotechnology Journal·2020· 36 cited
The single-use fixed bed bioreactors in viral vector production
2020Open Access
Development of Large-Scale Downstream Processing for Lentiviral Vectors
Molecular Therapy — Methods & Clinical Development·2020· 66 citedOpen Access
Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production
Human Gene Therapy·2020· 26 citedOpen Access
Detection of lentiviral suicide gene therapy in C6 rat glioma using hyperpolarised [1‐<sup>13</sup>C]pyruvate
NMR in Biomedicine·2020· 6 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Seppo Ylä‐Herttuala(40), Minna U. Kaikkonen(14), Hanna Leinonen(13), Kari J. Airenne(13), Jere T. Pikkarainen(12), Haritha Samaranayake(10), Ann‐Marie Määttä(10), Eevi M. Lipponen(9), Nigel Parker(7), Vesa Turkki(6), Piia Käyhty(6), Anniina J. Valkama(5), Tommi Heikura(5), Anna‐Kaisa Ruotsalainen(5), Heidi M. Laitinen(5), Suvi Linna-Kuosmanen(5), Emilia Kansanen(5), Jari P. Lappalainen(5), Anna–Liisa Levonen(5), Piia Valonen(5)